Asuragen Scientific Publications

Asuragen has researched and published extensively in genetics, oncology, molecular diagnostics, and technology advancements for over 15 years. These publications, posters, and white papers cover various disease areas and their related genes including fragile X (FMR1), spinal muscular atrophy (SMN1/SMN2), cystic fibrosis (CFTR), and chronic myeloid leukemia (BCR-ABL1). They show the power of detecting and interpreting molecular alterations using AmplideX and QuantideX technologies as well as the value of Molecular Quality Controls and companion diagnostics collaborations to deliver new insights and advance precision medicine. Simply search by term, filter by category, or use both to find your area of interest.

We’re driven to provide people with better answers, so we ensure our products are supported by reliable data and backed by rigorous science. Dive into these publications to learn more.

Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows
John N. Milligan, Laura Blasco-Pérez, Mar Costa-Roger, Marta Codina-Solà, and Eduardo F. Tizzano
A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials
MW Lutz, DK Burns, R Alexander, M Culp, D Yarnall, S Haneline, C Chiang, E Lai, C Metz, S Sundseth, T Guennel, S Marshall, BF Andruss, GJ Latham, B Hall, SN Statt, T Swanson, E Ratti and AM Saunders
Refining reproductive risk for FMR1 premutation carriers in the general obstetric population
Owens KM, et al. Am J Med Genet A. 2022 Feb. doi: 10.1002/ajmg.a.62666
Adoption of array technologies into the clinical laboratory
Hadd AG, et al.Expert Rev Mol Diagn. 2005 May;5(3):409-20.
Back To